Sclerosing mesenteritis

Sclerosing mesenteritis is a rare and relatively recently described disease of the abdominal cavity, characterized by inflammation and fibrosis of the mesenteric tissues, leading to their thickening and hardening. This can lead to the development of various symptoms from the abdominal organs, including abdominal pain, impaired intestinal motility and the development of intestinal obstruction. The relevance of the problem lies in the variety of clinical manifestations, which complicates diagnosis and requires a multidisciplinary approach to treatment. The pathogenesis of this disease is still the subject of active research, but its association with inflammatory processes, autoimmune diseases and sometimes with previous abdominal surgery is assumed.

History of the disease and interesting historical facts

Sclerosing mesenteritis was first described in the 1920s, when some researchers began documenting cases of unexplained inflammatory processes in the mesentery. Despite this, the disease remained in the shadow of other more well-known pathologies for a long time, and only in recent decades has it attracted the attention of both gastroenterologists and surgeons. Remarkably, in the scientific literature, one can find cases where sclerosing mesenteritis was mistakenly interpreted as a neoplasm or other pathologies, which emphasizes its difficulty in diagnosis. The development of modern imaging techniques such as MRI and CT have significantly improved the diagnosis, allowing this disease to be differentiated from other intestinal diseases.

Epidemiology

According to current data, the prevalence of sclerosing mesenteritis varies from 0.1 to 1 case per 100,000 people per year. The disease is most common in middle-aged people, with a peak incidence between the ages of 50 and 70 years. Men are affected 2-4 times more often than women. Some communities and populations may have higher incidence rates, which may be due to genetic or environmental factors. However, the diversity of statistical data indicates the need for further epidemiological studies to better understand this pathology.

Genetic predisposition to this disease

Studies of genetic predisposition to sclerosing mesenteritis have revealed that certain genes may be involved in the pathogenesis of the disease. The most notable is the association with mutations in genes associated with inflammatory processes, such as IL-6 and TNF-α. These genes play a key role in the immune response and can contribute to long-term inflammatory reactions, which in turn lead to fibrotic changes in tissue. In addition, there are cases where the disease developed against the background of other autoimmune processes, which may also indicate a genetic predisposition.

Risk factors for the development of this disease

There are several risk factors that may contribute to the development of sclerosing mesenteritis:

• Previous surgical operations on abdominal organs, especially resections and operations on the intestines.
• Inflammatory bowel diseases (eg, Crohn's disease, ulcerative colitis).
• Autoimmune diseases such as systemic lupus erythematosus.
• Some infectious diseases (for example, tuberculosis or Salmonella infection).
• Smoking and related lifestyle factors such as poor diet and alcohol abuse.

Diagnosis of this disease

Diagnosis of sclerosing mesenteritis is based on a combination of clinical manifestations, laboratory and radiological methods:

• Main symptoms: abdominal pain, diarrhea, weight loss, intestinal obstruction.
• Laboratory tests: general and biochemical blood tests, determination of the level of inflammatory markers (for example, C-reactive protein).
• Radiological examinations: computed tomography (CT) and magnetic resonance imaging (MRI) to visualize mesenteric changes.
• Other types of diagnostics: ultrasound and, in some cases, laparoscopy.
• Differential diagnosis: exclusion of neoplasms, vascular diseases, and other inflammatory bowel diseases.

Treatment

Treatment of sclerosing mesenteritis requires an individual approach and may include both medicinal and surgical methods:

• General treatment: optimization of diet, prescription of symptomatic agents.
• Pharmacological treatment: nonsteroidal anti-inflammatory drugs, glucocorticosteroids, immunosuppressants.
• Surgical treatment: resection of affected areas of the intestine in the presence of obstruction or other complications.
• Other types of treatment: physiotherapy, use of drugs to improve intestinal motility.

List of medications used to treat this disease

The main drug interventions include:

• Mesalazine
• Prednisolone
• Azathioprine
• Methotrexate
• Nonsteroidal anti-inflammatory drugs (eg, Ibuprofen)

Disease monitoring

Monitoring of a patient with sclerosing mesenteritis includes regular CT and general blood tests, symptom control, and periodic imaging. The prognosis depends on the extent of the lesion and the timeliness of treatment, but in general the disease can be chronic with the possibility of exacerbations. Complications may include intestinal obstruction, intestinal perforation, and the development of secondary infections, which require more intensive therapy.

Age-related features of the disease

Sclerosing mesenteritis may manifest itself differently in different age groups. In younger patients, the disease may have a more acute course, while in older people it often occurs with less pronounced symptoms, which in turn complicates diagnosis. Also, older people may have concomitant diseases that complicate treatment and require a comprehensive approach.

Questions and Answers

• What are the main symptoms of sclerosing mesenteritis? The main symptoms include abdominal pain, diarrhea, weight loss and intestinal obstruction.
• How is this disease diagnosed? Diagnosis is based on clinical presentation, laboratory tests and radiological methods such as CT and MRI.
• What treatment is indicated for sclerosing mesenteritis? Treatment includes drug therapy, surgical interventions and general measures to improve the patient's condition.
• What is the duration of treatment for this disease? The duration of treatment varies depending on the severity of the disease and can take from several months to several years.
• Is there a risk of relapse? Yes, sclerosing mesenteritis can be chronic with the possibility of relapse, which requires constant monitoring of the patient's condition.